Serotonin News and Research

Latest Serotonin News and Research

New findings suggest link between increased cholesterol, depression

Most people know that high cholesterol levels place them at increased risk for heart disease and stroke. Prior research has shown that particular types of strokes contribute to one's risk for depression, and that abnormal blood lipid levels can increase the risk of depression in the elderly.

21 Jul 2010

Forest Laboratories reports first-quarter diluted EPS of $0.39

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.

20 Jul 2010

MDMA (Ecstasy) holds promise for chronic treatment-resistant PTSD

MDMA (-3,4-methylenedioxymethamphetamine, also known as Ecstasy), may one day offer hope for individuals with posttraumatic stress disorder (PTSD), even people for whom other treatments have failed. Clinical trial results out today in the Journal of Psychopharmacology, published by SAGE, suggests that MDMA can be administered to subjects with PTSD without evidence of harm and could offer sufferers a vital window with reduced fear responses where psychotherapy can take effect.

20 Jul 2010

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.

1 Jul 2010

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced today that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition.

1 Jul 2010

Studies link anti-cholesterol statin drugs to increased risk of anxiety and depression

Scientists are reporting a possible explanation for the symptoms of anxiety and depression that occur in some patients taking the popular statin family of anti-cholesterol drugs, and reported by some individuals on low-cholesterol diets. These symptoms could result from long-term, low levels of cholesterol in the brain, the report suggests. It appears in ACS' weekly journal Biochemistry.

1 Jul 2010

New hope for patients with drug-resistant depression

New research shows that a unique strain of laboratory mice characterized at Penn State University has behavioral, hormonal, and neurochemical characteristics that are similar to those of human patients with drug-resistant forms of depression.

30 Jun 2010

Serotonin promotes beta cell expansion during pregnancy, offers possible cure for type 1 diabetes

Researchers funded by JDRF have discovered that the hormone, serotonin, may be involved in the increase of insulin-producing beta cells during pregnancy.

29 Jun 2010

A natural approach to combat stress

For anyone who knows the racing, "misfiring" brain associated with today's multitasking lifestyles, finding a safe, effective remedy to achieve calm can be a challenge. Women-run Rainbow Light® Nutritional Systems, a leader in natural nutrition for nearly 30 years, has developed a breakthrough remedy to calm the "busy brain" that can impair mental clarity and cause restless sleep.

29 Jun 2010

Combination therapy for severe depression

Severe depression is life threatening. So it is worth every effort to get depression under control and make life more manageable. For most people, that means some combination of antidepressant drugs and talk therapy.

29 Jun 2010

Arena's lorcaserin reduces body weight across patient subgroups

Arena Pharmaceuticals, Inc. today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined by gender, age, ethnicity and starting body weight and Body Mass Index (BMI). Greater improvements in cardiovascular risk factors were also achieved with lorcaserin treatment compared to placebo overall and in most subgroups.

28 Jun 2010

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

The cause of diabetes during pregnancy is directly controlled by serotonin, a chemical produced by the body and normally known as a neurotransmitter, and is influenced by the amount of protein in the mother's diet early in pregnancy, according to new findings of an international team led by researchers at UCSF.

28 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

AstraZeneca and Targacept, Inc., today announced the enrollment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker.

23 Jun 2010

TheraQuest launches new analgesic product pipeline

TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline. TheraQuest also announced the launch of its new corporate website at http://www.theraquestinc.com.

23 Jun 2010

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

A team of bioengineers from the University of Pennsylvania Institute for Medicine and Engineering have trained a computer neural network model to accurately predict how blood platelets would respond to complex conditions found during a heart attack or stroke.

21 Jun 2010

Serotonin transporter gene appears to increase one's risk for depression, PTSD: Study

There is a great deal of interest in factors that contribute to the vulnerability to developing post-traumatic stress disorder, or PTSD. One factor that appears to contribute to the heritable vulnerability to PTSD is a variation in the gene that codes for the serotonin transporter, also known as the serotonin uptake site. Having a shorter version of the serotonin transporter gene appears to increase one's risk for depression and PTSD after exposure to extremely stressful situations.

18 Jun 2010

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Within the first week after giving birth, up to 70 percent of all women experience symptoms of the baby blues. While most women recover quickly, up to 13 percent of all new mothers suffer from symptoms of a clinical-level postpartum depression. Postpartum depression is defined as a major depressive episode starting within 4 weeks after delivery and is a significant public health problem. Postpartum blues represents a major risk factor for developing postpartum depression and severe postpartum blues symptoms can be viewed as a prodromal stage for postpartum depression.

17 Jun 2010

3 new genes in genetic research of suicidal behaviour

Three genes that have barely been studied to date have now provided fresh knowledge about patients with suicidal backgrounds. This is the result of a study by a team of Spanish researchers at Mount Sinai Hospital and Columbia University in the City of New York (United States), which found that several mutations are involved. This finding could help to develop future genetic tests to identify predisposition to suicide, without ignoring the importance of social and cultural factors.

16 Jun 2010

Serotonin News and Research

Latest Serotonin News and Research

New findings suggest link between increased cholesterol, depression

Forest Laboratories reports first-quarter diluted EPS of $0.39

MDMA (Ecstasy) holds promise for chronic treatment-resistant PTSD

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Studies link anti-cholesterol statin drugs to increased risk of anxiety and depression

New hope for patients with drug-resistant depression

Serotonin promotes beta cell expansion during pregnancy, offers possible cure for type 1 diabetes

A natural approach to combat stress

Combination therapy for severe depression

Arena's lorcaserin reduces body weight across patient subgroups

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

TheraQuest launches new analgesic product pipeline

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

Serotonin transporter gene appears to increase one's risk for depression, PTSD: Study

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

3 new genes in genetic research of suicidal behaviour

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Serotonin News and Research

Latest Serotonin News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in